Extracellular vesicles as antigen carriers for novel vaccination avenues.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Name:
Mehanny, Lehr and Fuhrmann.pdf
Size:
5.092Mb
Format:
PDF
Description:
accepted manuscript
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Issue Date
2021-03-26
Metadata
Show full item recordAbstract
Antigen delivery has always been a challenge in scientific practice of vaccine formulation. Yet, mammalian extracellular vesicles (EVs) or bacterial membrane vesicles (MVs) provide an innovative avenue for safe and effective delivery of antigenic material. They include intrinsically loaded antigens from EV-secreting cells or extrinsically loaded antigens onto pre-formed vesicles. Interestingly, many studies shed light on potential novel anti-cancer vaccination immunotherapy for therapeutic applications from mammalian cell host-derived EVs, as well as conventional vaccination for prophylactic applications using bacterial cell-derived MVs against infectious diseases. Here, we discuss the rationale, status quo and potential for both vaccine applications using EVs.Citation
Adv Drug Deliv Rev. 2021 Mar 26;173:164-180. doi: 10.1016/j.addr.2021.03.016. Epub ahead of print.Affiliation
HIPS, Helmholtz-Institut für Pharmazeutische Forschung Saarland, Universitätscampus E8.1 66123 Saarbrücken, Germany.Publisher
ElsevierJournal
Advanced drug delivery reviewsPubMed ID
33775707Type
ReviewLanguage
enEISSN
1872-8294ae974a485f413a2113503eed53cd6c53
10.1016/j.addr.2021.03.016
Scopus Count
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International